Chugai and Alebund enter option and license deal for EOS789

10 July 2021

Japanese drug major Chugai Pharmaceuticals (TYO: 4519) has entered into an option and license agreement with Chinese biotech Alebund Pharmaceuticals (Hong Kong), regarding Chugai’s EOS789, an investigational agent under development for hyperphosphatemia.

EOS789 is an oral inhibitor of phosphate transporters, NaPi-IIb, PiT-1, PiT-2, which was discovered by Chugai and studied in Phase I clinical trial. After entering into the agreement, Alebund, which in May this year raised $60 million in its Series B financing round, plans to conduct an early-stage efficacy clinical trial to further evaluate EOS789. If Alebund exercises the option, Chugai will grant Alebund an exclusive license to develop, manufacture, and commercialize EOS789 for all indications worldwide including Japan.

Financial terms of accord

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK